Intra-arterial Albumin in Acute Ischemic Stroke After Endovascular Treatment for
- Conditions
- Acute Ischemic Stroke
- Interventions
- Other: mechanical thrombectomy and a standard clinical therapyDrug: intra-arterial infusion albumin
- Registration Number
- NCT06172387
- Lead Sponsor
- Tianjin Huanhu Hospital
- Brief Summary
Stroke is an acute focal injury of the central nervous system caused by cerebral vessels. One in every four people is affected by stroke at different times in life. Globally, stroke is the second leading cause of death and third leading cause of disability in adults. we hypothesized that in patients with acute large vessel occlusive ischemic stroke treated with mechanical thrombectomy, the infusion of 20% human serum albumin solution into the revascularization area can exert a stronger neuroprotective effect.
- Detailed Description
In the previous period, we have conducted a clinical trial on the safety and feasibility of arterial infusion of 20% human serum albumin solution. The results of the study found that after arterial infusion of 20% human serum albumin solution at a dose of 0.6g/kg to the subject's vascularization area, the subjects did not develop significant complications related to albumin solution. There were no serious adverse events associated with arterial infusion of albumin solution in all subjects. After the evaluation of the Data Safety Monitoring Board, the clinical study was considered to be the next step, which is to initially explore the effectiveness of 0.6g/kg arterial infusion of 20% human serum albumin solution for neuroprotection of subjects.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 46
1.Male or female, age≥18 and ≤ 80; 2. anterior circulation large vessel occlusion confirmed by CTA, MRA and DSA; 3. baseline National Institute of Health Stroke Scale (NIHSS) score ≥6； 4. Alberta Stroke Program Early CT Score (ASPECTS) 6-10; 5. Stroke symptoms present to femoral artery or brachial artery puncture within 24 hours； 6. occluded vessel reaches eTICI level ≥2b after thrombectomy confirmed by DSA；7. Informed consent obtained;
(1) history of congestive heart failure or jugular dilatation, third heart sound, resting tachycardia due to heart failure (>100 beats/min), hepatomegaly and lower limb edema without obvious cause on admission physical examination; (2) hospitalization for acute myocardial infarction within 3 months; (3) symptoms of acute myocardial infarction or admission electrocardiogram; (4) second or third degree heart block or arrhythmia with hemodynamic instability; (5) acute or chronic renal failure (blood creatinine > 2.0 mg/dL); (6) severe anemia (hematocrit<32%); (7) symptoms or CT evidence of subarachnoid hemorrhage; (8) pregnancy; (9) allergy to albumin; (10) admission blood pressure higher than 185/110 mmHg; (11) any chronic lung disease, including chronic obstructive pulmonary disease, bronchiectasis, and other lung diseases that interfere with daily activities; (12) presence of other diseases that may endanger life.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description sham group mechanical thrombectomy and a standard clinical therapy All participants have no intra-arterial albumin. intra-arterial group intra-arterial infusion albumin 20% human serum albumin (0.6g/kg) solution will be injected into the artery after revascularization in acute ischemic stroke. All participants will receive mechanical thrombectomy and a standard clinical therapy. intra-arterial group mechanical thrombectomy and a standard clinical therapy 20% human serum albumin (0.6g/kg) solution will be injected into the artery after revascularization in acute ischemic stroke. All participants will receive mechanical thrombectomy and a standard clinical therapy.
- Primary Outcome Measures
Name Time Method cerebral infarct volume 24-48 hours after randomization infarct volume is evaluated mainly through brain MRI
- Secondary Outcome Measures
Name Time Method scores assessed by National Institutes of Health Stroke Scale (NIHSS) 24 ± 6 hours, 48 ± 12 hours, 7 ± 2 days, 90 ±10 days after randomization the NIHSS is a stroke severity score that is composed of 11 items, range from 0 to 42, higher values indicate more severe deficits
modified Rankin Scale score(mRS) 90 ±10 days after randomization the mRS is an ordinal disability score of 7 categories (0=no symptoms to 5=severe disability, and 6=death)
any intracranial hemorrhage on follow-up imaging 24 (12 to 36) hours imaging safety endpoints; per ECASSIII definition and per Heidelberg bleeding classification
symptomatic intracerebral hemorrhage 24 (12 to 36) hours imaging safety endpoints; deterioration in NIHSS score of ≥4 point within 24 hours;per ECASS III definition and per Heidelberg bleeding classification
the good prognosis at 90 days assessed by mRS 90 ±10 days after randomization the mRS is an ordinal disability score of 7 categories (0=no symptoms to 5=severe disability, and 6=death)
improvement of neurologic function after 24 hours 24 ± 6 hours after randomization NIHSS score decreased by more than 4 points or NIHSS score was 0; secondary clinical efficacy endpoint; the NIHSS is a stroke severity score composed of 11 items (range from 0 to 42, higher values indicate more severs deficits)
Barthel index (BI) 90 ±10 days after randomization the BI is an ordinal disability score of 10 categories (range from 0-100, higher values indicate better prognosis)
mRS4-6 90 ± 10 days after randomization secondary clinical efficacy endpoint;the mRs is an ordinal disability score of 7 categories (0 = no symptoms to 5 = severe disability, and 6 = death)
change in National Institutes of Health Stroke Scale (NIHSS) score from baseline to 24 hours from baseline to 24 ± 6 hours the NIHSS is a stroke severity score that is composed of 11 items, range from 0 to 42, higher values indicate more severe deficits
revascularization on follow-up imaging 24 (16 to 36) hours secondary imaging efficacy endpoint
24-hours neurologic deterioration 24 ± 6 hours after randomization NIHSS score increased by more than 4 points; the NIHSS is a stroke severity score composed of 11 items (range from 0 to 42, higher values indicate more severe deficits); clinical safety endpoint
Mortality 90 ± 10 days after randomization clinical safety endpoint
Survival rates 7 ± 2 days, 90 ± 10 days after randomization secondary clinical efficacy endpoint
Stroke recurrence 90 ± 10 days after randomization clinical safety endpoint
Trial Locations
- Locations (1)
Ming wei
🇨🇳Tianjin, China, Tianjin, China